Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2022-03-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
海创药业首次公开发行股票并在科创板上市招股意向书附录
Regulatory Filings Classification · 95% confidence The document is titled as a "发行保荐书" (Sponsorship Letter) related to the company's initial public offering (IPO) and listing on the Science and Technology Innovation Board (科创板). It includes detailed sections on the underwriting institution's commitment, due diligence, legal and audit reports, internal control reports, and extensive information about the company's governance, financials, risks, and compliance with regulatory requirements for IPO. The document is lengthy (15,000 characters) and contains substantive financial and operational information, including audit reports and internal control verification, which are typical components of IPO prospectus or sponsorship documents. This type of document is not an annual report, earnings release, or a simple announcement but a comprehensive regulatory filing related to the IPO process. It does not fit into categories like Annual Report (10-K), Earnings Release (ER), or Management Reports (MDA). It is a regulatory filing specific to the IPO process, including audit and legal opinions, but not a standalone audit report or a proxy statement. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not neatly fit into other categories.
2022-03-21 Chinese
海创药业首次公开发行股票并在科创板上市发行安排及初步询价公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Haichuang Pharmaceutical Co., Ltd. on the STAR Market (科创板) of the Shanghai Stock Exchange. It includes extensive information about the issuance arrangement, preliminary inquiry, strategic placement, investor qualifications, pricing, allotment, and related regulatory compliance. The document references regulatory bodies such as the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange, and includes detailed procedural and regulatory information about the IPO process. It is not a financial report, earnings release, or management discussion, but rather a comprehensive announcement about the capital raising and share issuance process. Therefore, the document fits best into the category of Capital/Financing Update (CAP).
2022-03-21 Chinese
海创药业首次公开发行股票并在科创板上市招股意向书
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) and listing on the Shanghai Stock Exchange Science and Technology Innovation Board (科创板). It includes extensive information about the company's business, risks, financial data, and the terms of the stock issuance. The document is titled 招股意向书 (Prospectus or Offering Intention Document), which is a formal document used in capital market transactions to inform investors about the offering. It contains detailed financial data, risk factors, and operational information but is not an annual or quarterly financial report, nor is it a simple announcement or presentation. This type of document fits the category of Capital/Financing Update (CAP) as it relates to the company's fundraising and capital structure changes through a public offering.
2022-03-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.